Silverberg, J.I., Rosmarin, D., Chovatiya, R.  et al.  The regulatory T cell-selective interleukin-2 receptoragonist rezpegaldesleukin in the treatment of inflammatory ...

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

Opens in a new tab or window Once-daily roflumilast cream at 0.15% improved symptoms of atopic ... a range of treatments, unmet needs persist. First, crisaborole and the topical calcineurin ...

Atopic dermatitis skin is deficient in antimicrobial ... the induction of corticosteroid insensitivity, which complicates treatment response to corticosteroid therapy in patients with AD (Hauk ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do not address the multiple inflammatory pathways that cause its specific ...

Dupilumab is prescribed for treating moderate-to-severe atopic dermatitis in adult patients who do not respond to topical treatments or cannot tolerate standard therapies. It acts as an ...

Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...